Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 93, Issue 5, Pages 655-663
Publisher
Wiley
Online
2018-02-03
DOI
10.1002/ajh.25057
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information
- (2018) Paola Minetto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Gemtuzumab ozogamicin in acute myeloid leukemia
- (2017) C D Godwin et al. LEUKEMIA
- Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study
- (2017) Chiara Frairia et al. LEUKEMIA RESEARCH
- High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients
- (2016) Fabio Guolo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Why Is Progress in Acute Myeloid Leukemia So Slow?
- (2015) Elihu Estey SEMINARS IN HEMATOLOGY
- Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia
- (2014) J. Loke et al. ANNALS OF HEMATOLOGY
- Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials
- (2014) X. Li et al. ANNALS OF ONCOLOGY
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
- (2014) Alan S. Gamis et al. JOURNAL OF CLINICAL ONCOLOGY
- The Leukemias: A Half-Century of Discovery
- (2014) Emil J. Freireich et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
- (2013) Sylvain Pilorge et al. AMERICAN JOURNAL OF HEMATOLOGY
- Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
- (2013) J. M. Rowe et al. BLOOD
- Why is it so difficult to use gemtuzumab ozogamicin?
- (2013) BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Gemtuzumab Ozogamicin: Time to Resurrect?
- (2012) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of AML: resurrection for gemtuzumab ozogamicin?
- (2012) Elihu Estey LANCET
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia
- (2011) Todd M. Cooper et al. CANCER
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
- (2008) Roberto Stasi et al. CANCER TREATMENT REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More